Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282672 · ClinicalTrials.gov registry record · NA
Ablation of Intestinal Metaplasia Containing Dysplasia
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 127
- Enrollment target
NCT00282672: Completed NA study, sponsored by Medtronic - MITG.
NCT00282672 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 127 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282672, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett's Esophagus.
Primary Outcome
% of patients with complete eradication of IM out of the number of participants analyzed at 12 month was calculated.
Interventions
- DEVICE Ablation System plus anti-secretory medication
- DEVICE Sham procedure plus anti-secretory medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2006-02 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT00282672 record still lists
NCT00282672 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Ablation System plus anti-secretory medication is the first listed.
NCT00282672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00282672 about?
NCT00282672 is a clinical study titled "Ablation of Intestinal Metaplasia Containing Dysplasia". The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett's Esophagus.
What is the current status of trial NCT00282672?
This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2006-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00282672?
The interventions under investigation include: Ablation System plus anti-secretory medication (DEVICE), Sham procedure plus anti-secretory medication (DEVICE).
Who is sponsoring clinical trial NCT00282672?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00282672's enrollment target sits among peer trials
127 749th of 2000 higher than 1,252 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia